Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)

Mise à jour : Il y a 4 ans
Référence : NCT00191139

Femme et Homme

Extrait

To assess the 2 year survival of patients with Stage III unresectable non-small cell lung cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent chemotherapy and radiation.


Critère d'inclusion

  • non-small cell lung cancer


Liens